Evolus (EOLS) to Release Quarterly Earnings on Wednesday

Evolus (NASDAQ:EOLS) will be announcing its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Evolus Stock Performance

Evolus stock opened at $16.75 on Monday. The company has a market cap of $1.06 billion, a PE ratio of -18.41 and a beta of 1.31. Evolus has a 12 month low of $7.67 and a 12 month high of $17.82. The company has a fifty day moving average price of $16.25 and a two-hundred day moving average price of $13.72. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on EOLS shares. Barclays increased their price objective on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Evolus in a research report on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a research note on Monday, September 16th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Friday, September 13th.

Insider Transactions at Evolus

In other Evolus news, CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the transaction, the chief marketing officer now owns 82,375 shares in the company, valued at $1,305,643.75. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the sale, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.